Vericel (NASDAQ:VCEL) Stock: Insider Jonathan Siegal Sells 1,500 Shares

Vericel Corporation (NASDAQ:VCEL) insider Jonathan Siegal sold 1,500 shares of the company’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $52.90, for a total transaction of $79,350.00. Following the transaction, the insider owned 1,259 shares in the company, valued at $66,601.10. The trade was a 54.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Vericel Stock Performance

Shares of VCEL stock opened at $54.62 on Friday. The stock has a market cap of $2.80 billion, a PE ratio of 85.35 and a beta of 1.08. Vericel Corporation has a 1 year low of $28.95 and a 1 year high of $55.60. The stock has a fifty day moving average price of $41.01 and a 200 day moving average price of $38.90.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.06 by $0.21. Vericel had a net margin of 10.27% and a return on equity of 9.09%. The business had revenue of $85.37 million for the quarter, compared to analyst estimates of $77.95 million. During the same period in the previous year, the firm earned $0.10 EPS. The business’s revenue for the quarter was up 26.5% compared to the same quarter last year. As a group, equities research analysts predict that Vericel Corporation will post 0.54 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. HC Wainwright increased their target price on Vericel from $72.00 to $75.00 and gave the company a “buy” rating in a report on Friday. Truist Financial set a $65.00 price objective on Vericel in a research report on Friday. Canaccord Genuity Group set a $60.00 price objective on Vericel in a research note on Thursday, July 30th. Wall Street Zen raised Vericel from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Vericel in a research report on Thursday, October 29th. Four analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.80.

More Vericel News

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported Q3 revenue of $85.4 million, up 26.5% year over year and above the $78.0 million consensus. Earnings per share of $0.27 also topped estimates of $0.06, while net income rose 179% to $14.2 million. Vericel Q3 results and guidance
• Positive Sentiment: The company raised its FY2026 revenue outlook to $344 million–$346 million, above analyst expectations of roughly $336 million, and lifted its adjusted EBITDA margin guidance to 28%. The stronger outlook, alongside record MACI sales, helped fuel investor optimism. Vericel shares rise on record revenue and higher outlook
• Positive Sentiment: HC Wainwright raised its price target to $75 from $72 and maintained a Buy rating, signaling continued analyst confidence in the stock’s prospects. HC Wainwright price target update
• Negative Sentiment: Several Vericel directors and insiders disclosed stock sales totaling about 22,000 shares on November 4–5. One insider’s sale reduced their reported stake by 88%, which may be a near-term concern for investors, though insider sales alone do not establish a negative outlook. SEC insider transaction filing

Institutional Trading of Vericel

A number of hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC increased its stake in shares of Vericel by 17.7% in the second quarter. GAMMA Investing LLC now owns 1,886 shares of the biotechnology company’s stock worth $84,000 after acquiring an additional 283 shares during the last quarter. Kopp Family Office LLC boosted its position in Vericel by 0.6% during the third quarter. Kopp Family Office LLC now owns 51,352 shares of the biotechnology company’s stock valued at $2,061,000 after purchasing an additional 299 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its position in Vericel by 0.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 157,081 shares of the biotechnology company’s stock valued at $6,195,000 after purchasing an additional 435 shares during the last quarter. Handelsbanken Fonder AB grew its stake in Vericel by 2.2% in the second quarter. Handelsbanken Fonder AB now owns 23,079 shares of the biotechnology company’s stock valued at $1,027,000 after purchasing an additional 500 shares in the last quarter. Finally, Gagnon Securities LLC increased its position in Vericel by 7.3% in the 3rd quarter. Gagnon Securities LLC now owns 7,839 shares of the biotechnology company’s stock worth $315,000 after purchasing an additional 536 shares during the last quarter.

About Vericel

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.